{"podcast":{"title":"Health News Today | 2 Min News | The Daily News Now!","slug":"health-news-today-2-min-news-the-daily-news-now-7685759","podcast_index_feed_id":7685759,"rss_url":"https://feeds.fastcast.ai/health-and-fitness-news-today-2-min-news-the-daily-news-now.xml","website_url":null,"image_url":"https://image.fastcast.ai/cover/01017222-be18-4060-a2b6-ae821dbc23fa.png","author":"The Daily News Now!","episode_count":65,"summary":"Hosted by Corey with the Story, Health and Fitness News Today delivers fast, focused daily updates on the stories shaping health, wellness, and performance—from fitness trends and nutrition to medical breakthroughs and lifestyle insights. Designed for quick, on-the-go listening, each episode brings you up to speed in minutes. Produced by AI for speed, consistency, and global scale, the show is part of The Daily News Now network—covering the topics that impact your everyday life and keeping you informed. Health and Fitness News Today is your daily snapshot of what’s happening in health and wellness. Advertise on DNN: advertise@thednn.ai","last_synced_at":"2026-09-18T04:22:25.318567+00:00","page_url":"https://stenobird.com/podcast/health-news-today-2-min-news-the-daily-news-now-7685759"},"episode":{"title":"Retatrutide: The Triple-Hormone Weight Breakthrough | Health and Fitness News","slug":"retatrutide-the-triple-hormone-weight-breakthrough-health-and-fitness-news","published_at":"2026-07-24T05:09:27+00:00","page_url":"https://stenobird.com/podcast/health-news-today-2-min-news-the-daily-news-now-7685759/retatrutide-the-triple-hormone-weight-breakthrough-health-and-fitness-news","show_page_url":"https://stenobird.com/podcast/health-news-today-2-min-news-the-daily-news-now-7685759","url":"https://sources.thednn.ai/e2621ad3b7a0f446","audio_url":"https://api.fastcast.ai/audio/22f18bdb-1237-4e26-8705-4fc459daaa96.mp3","summary":"Eli Lilly’s experimental drug retatrutide is blowing the weight loss and diabetes world away—showing up to 23% body weight loss and stellar blood sugar control in phase three trials. Unlike Ozempic or Mounjaro, it hits three hormone receptors (GLP-1, GIP, glucagon) for a triple-threat approach, delivered weekly via injection. It’s already impressing in trials for both type two diabetes and severe obesity with heart disease, even outperforming expectations in the diabetes group. But don’t ignore the downsides: diarrhea, nausea, and constipation plagued many, with over 10% discontinuing treatment. Still, with FDA approval potentially on the horizon by early 2027, retatrutide could redefine how we tackle obesity and metabolic disease. Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN: advertise@thednn.ai This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai. View sources & latest updates: https://sources.thednn.ai/e2621ad3b7a0f446","meta_description":"Eli Lilly’s experimental drug retatrutide is blowing the weight loss and diabetes world away—showing up to 23% body weight loss and stellar blood sugar co…","key_points":[],"chapters":[],"topics":[],"duration_seconds":121,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/health-news-today-2-min-news-the-daily-news-now-7685759/episodes/retatrutide-the-triple-hormone-weight-breakthrough-health-and-fitness-news/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/health-news-today-2-min-news-the-daily-news-now-7685759/retatrutide-the-triple-hormone-weight-breakthrough-health-and-fitness-news.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}